Adaptable and scalable electroporation for cellular therapy
Ended Project Grant Awarded Last action
- Award ID
- R43GM148147
- Recipient
-
Cytequest Inc. UEI M9JJW8NSEDS5
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $550,446
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Place of performance
- Ithaca, NY, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cellular therapies have demonstrated the potential to treat a variety of inherited and acquired diseases, but the first generation of approved cell therapies rely on viral vectors for cellular reprogramming. Viral vectors are recognized as a bottleneck in the development of these therapies and other delivery methods, like electroporation, are being clinically investigated. To address limitations in existing electroporation technology, cytequest is developing a simple, scalable electroporation platform to optimize transfection parameters and deliver cargo efficiently and reproducibly at high throughput. Cytequest's platform consists of a planar flow chip with a thin slab geometry that ensures that cells are subject to a uniform electrical field for reproducible electroporation. The flow cell geometry allows for seamless scaling to a high- volume system for delivery at clinical scale. The key objectives of this proposal are to: (1) demonstrate high-efficiency delivery of clinically relevant cargo including crispr/CAS9 ribonucleoprotein complexes to primary human t cells, and (2) construct a prototype large- volume electroporation flow system compatible with the volumetric throughput required for cellular therapy in a clinical setting. Cytequest will demonstrate that the optimized electroporation parameters of the small volume system can be used directly in the high-volume system with less than 5% variation in the biomolecular delivery efficiency and cell viability. The high-volume electroporation flow system can be manufactured in a process that is cost-effective and robust. Cytequest ultimately aims to use this novel platform in conjunction with crispr/CAS9 technology as a therapeutic application for adoptive cell therapy.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $275,223 | |
| Original award | $275,223 |
Quick answers
Who received award R43GM148147?
R43GM148147 was awarded to Cytequest Inc. by National Institute of General Medical Sciences (National Institutes of Health) on July 1, 2022.
How much is award R43GM148147 worth?
$550,446 has been obligated on R43GM148147.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award